

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number
WO 2004/058754 A1

(51) International Patent Classification⁷: C07D 417/12, 413/12, 403/12, 401/12, A61K 31/495, A61P 29/00, 13/00

(74) Agents: ABRAMS, Samuel, B. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(21) International Application Number:
PCT/US2003/041100

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
22 December 2003 (22.12.2003)

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(30) Priority Data:
60/435,917 24 December 2002 (24.12.2002) US

60/459,626 3 April 2003 (03.04.2003) US

60/473,856 29 May 2003 (29.05.2003) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(71) Applicant (*for all designated States except US*): EURO-CELTIQUE S.A. [LU/LU]; 122, boulevard de la Petrusse, L-2330 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SUN, Qun [CN/US]; 19 Aldgate Court, Princeton, NJ 08540 (US). TAFESSE, Laykea [ET/US]; 11 Abington Lane, Robbinsville, NJ 08691 (US). VICTORY, Sam [US/US]; 131 Winding Lane, Newtown, PA 18940 (US).

WO 2004/058754 A1

(54) Title: BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY



(57) Abstract: A compound of formula (I) wherein Ar₁, A, R₃, x, and m are as disclosed herein and Ar₂ is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a "Benzooazolylpiperazine Compound"), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of Benzoazolylpiperazine Compound are disclosed.

BENZAOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY

This application claims the benefit of U.S. Provisional Application No. 60/435,917, filed December 24, 2002; U.S. Provisional Application No. 60/459,626, filed April 3, 2003; and U.S. Provisional Application No. 60/473,856, filed May 29, 2003, all of which are incorporated herein by reference in their entirety.

1. FIELD OF THE INVENTION

The present invention relates to Benzoazolylpiperazine Compounds, compositions comprising a Benzoazolylpiperazine Compound and methods for treating or preventing pain, urinary incontinence (UI), an ulcer, inflammatory-bowel disease (IBD), irritable-bowel syndrome (IBS), an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression, comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound.

2. BACKGROUND OF THE INVENTION

Pain is the most common symptom for which patients seek medical advice and treatment. Pain can be acute or chronic. While acute pain is usually self-limited, chronic pain persists for 3 months or longer and can lead to significant changes in a patient's personality, lifestyle, functional ability and overall quality of life (K.M. Foley, *Pain, in Cecil Textbook of Medicine* 100-107 (J.C. Bennett and F. Plum eds., 20th ed. 1996)).

Pain has been traditionally managed by administering non-opioid analgesics, such as acetylsalicylic acid, choline magnesium trisalicylate, acetaminophen, ibuprofen, fenoprofen, diflusinal, and naproxen; or opioid analgesics, including morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, and oxymorphone. *Id.*

UI is uncontrollable urination, generally caused by bladder-detrusor-muscle instability. UI affects people of all ages and levels of physical health, both in health care settings and in the community at large. At present, UI afflicts 15-30% of elderly people living at home, one-third of those living in acute-care settings, and at least one-half of those

living in long-term care institutions (R.M. Resnick, *Lancet* 346:94 (1995)). Persons having UI are predisposed to also having urinary-tract infections, pressure ulcers, perineal rashes and urosepsis. Psychosocially, UI is associated with embarrassment, social stigmatization, depression and a risk of institutionalization (Herzo *et al.*, *Annu. Rev. Gerontol. Geriatr.* 9:74
5 (1989)). Economically, the costs of UI are great; in the United States alone, health-care costs associated with UI are over \$15 billion per annum.

Physiologic bladder contraction results in large part from acetylcholine-induced stimulation of post-ganglionic muscarinic-receptor sites on bladder smooth muscle. Treatments for UI include the administration of drugs having bladder-relaxant properties,
10 which help to control bladder-detrusor-muscle overactivity. For example, anticholinergics such as propantheline bromide and glycopyrrolate, and combinations of smooth-muscle relaxants such as a combination of racemic oxybutynin and dicyclomine or an anticholinergic, have been used to treat UI (See, e.g., A.J. Wein, *Urol. Clin. N. Am.* 22:557-577 (1995); Levin
15 *et al.*, *J. Urol.* 128:396-398 (1982); Cooke *et al.*, *S. Afr. Med. J.* 63:3 (1983); R.K. Mirakhur
et al., *Anaesthesia* 38:1195-1204 (1983)). These drugs are not effective, however, in all patients having uninhibited bladder contractions. Administration of anticholinergic medications represent the mainstay of this type of treatment.

None of the existing commercial drug treatments for UI, however, has achieved complete success in all classes of UI patients, nor has treatment occurred without
20 significant adverse side effects. For example, drowsiness, dry mouth, constipation, blurred vision, headaches, tachycardia, and cardiac arrhythmia, which are related to the anticholinergic activity of traditional anti-UI drugs, can occur frequently and adversely affect patient compliance. Yet despite the prevalence of unwanted anticholinergic effects in many patients, anticholinergic drugs are currently prescribed for patients having UI. *The Merck*
25 *Manual of Medical Information* 631-634 (R. Berkow ed., 1997).

Ulcers are sores occurring where the lining of the digestive tract has been eroded by stomach acids or digestive juices. The sores are typically well-defined round or oval lesions primarily occurring in the stomach and duodenum. About 1 in 10 people develop an ulcer. Ulcers develop as a result of an imbalance between acid-secretory factors, also
30 known as "aggressive factors," such as stomach acid, pepsin, and *Helicobacter pylori*

infection, and local mucosal-protective factors, such as secretion of bicarbonate, mucus, and prostaglandins.

Treatment of ulcers typically involves reducing or inhibiting the aggressive factors. For example, antacids such as aluminum hydroxide, magnesium hydroxide, sodium 5 bicarbonate, and calcium bicarbonate can be used to neutralize stomach acids. Antacids, however, can cause alkalosis, leading to nausea, headache, and weakness. Antacids can also interfere with the absorption of other drugs into the blood stream and cause diarrhea.

H_2 antagonists, such as cimetidine, ranitidine, famotidine, and nizatidine, are also used to treat ulcers. H_2 antagonists promote ulcer healing by reducing gastric acid and 10 digestive-enzyme secretion elicited by histamine and other H_2 agonists in the stomach and duodenum. H_2 antagonists, however, can cause breast enlargement and impotence in men, mental changes (especially in the elderly), headache, dizziness, nausea, myalgia, diarrhea, rash, and fever.

H^+, K^+ - ATPase inhibitors such as omeprazole and lansoprazole are also used 15 to treat ulcers. H^+, K^+ - ATPase inhibitors inhibit the production of enzymes used by the stomach to secrete acid. Side effects associated with H^+, K^+ - ATPase inhibitors include nausea, diarrhea, abdominal colic, headache, dizziness, somnolence, skin rashes, and transient elevations of plasma activities of aminotransferases.

Sucralfate is also used to treat ulcers. Sucralfate adheres to epithelial cells and 20 is believed to form a protective coating at the base of an ulcer to promote healing. Sucralfate, however, can cause constipation, dry mouth, and interfere with the absorption of other drugs.

Antibiotics are used when *Helicobacter pylori* is the underlying cause of the ulcer. Often antibiotic therapy is coupled with the administration of bismuth compounds such as bismuth subsalicylate and colloidal bismuth citrate. The bismuth compounds are 25 believed to enhance secretion of mucous and HCO_3^- , inhibit pepsin activity, and act as an antibacterial against *H. pylori*. Ingestion of bismuth compounds, however, can lead to elevated plasma concentrations of Bi^{+3} and can interfere with the absorption of other drugs.

Prostaglandin analogues, such as misoprostol, inhibit secretion of acid and stimulate the secretion of mucous and bicarbonate and are also used to treat ulcers, especially 30 ulcers in patients who require nonsteroidal anti-inflammatory drugs. Effective oral doses of

prostaglandin analogues, however, can cause diarrhea and abdominal cramping. In addition, some prostaglandin analogues are abortifacients.

Carbenoxolone, a mineral corticoid, can also be used to treat ulcers.

Carbenoxolone appears to alter the composition and quantity of mucous, thereby enhancing 5 the mucosal barrier. Carbenoxolone, however, can lead to Na⁺ and fluid retention, hypertension, hypokalemia, and impaired glucose tolerance.

Muscarinic cholinergic antagonists such as pirenzapine and telenzapine can also be used to reduce acid secretion and treat ulcers. Side effects of muscarinic cholinergic antagonists include dry mouth, blurred vision, and constipation. *The Merck Manual of* 10 *Medical Information* 496-500 (R. Berkow ed., 1997) and *Goodman and Gilman's The Pharmacological Basis of Therapeutics* 901-915 (J. Hardman and L. Limbird eds., 9th ed. 1996).

IBD is a chronic disorder in which the bowel becomes inflamed, often causing recurring abdominal cramps and diarrhea. The two types of IBD are Crohn's disease and 15 ulcerative colitis.

Crohn's disease, which can include regional enteritis, granulomatous ileitis, and ileocolitis, is a chronic inflammation of the intestinal wall. Crohn's disease occurs equally in both sexes and is more common in Jews of eastern-European ancestry. Most cases of Crohn's disease begin before age 30 and the majority start between the ages of 14 and 24. 20 The disease typically affects the full thickness of the intestinal wall. Generally the disease affects the lowest portion of the small intestine (ileum) and the large intestine, but can occur in any part of the digestive tract.

Early symptoms of Crohn's disease are chronic diarrhea, crampy abdominal pain, fever, loss of appetite, and weight loss. Complications associated with Crohn's disease 25 include the development of intestinal obstructions, abnormal connecting channels (fistulas), and abscesses. The risk of cancer of the large intestine is increased in people who have Crohn's disease. Often Crohn's disease is associated with other disorders such as gallstones, inadequate absorption of nutrients, amyloidosis, arthritis, episcleritis, aphthous stomatitis, erythema nodosum, pyoderma gangrenosum, ankylosing spondylitis, sacroilitis, uveitis, and 30 primary sclerosing cholangitis. There is no known cure for Crohn's disease.

Cramps and diarrhea, side effects associated with Crohn's disease, can be relieved by anticholinergic drugs, diphenoxylate, loperamide, deodorized opium tincture, or codeine. Generally, the drug is taken orally before a meal.

Broad-spectrum antibiotics are often administered to treat the symptoms of Crohn's disease. The antibiotic metronidazole is often administered when the disease affects the large intestine or causes abscesses and fistulas around the anus. Long-term use of metronidazole, however, can damage nerves, resulting in pins-and-needles sensations in the arms and legs. Sulfasalazine and chemically related drugs can suppress mild inflammation, especially in the large intestine. These drugs, however, are less effective in sudden, severe flare-ups. Corticosteroids, such as prednisone, reduce fever and diarrhea and relieve abdominal pain and tenderness. Long-term corticosteroid therapy, however, invariably results in serious side effects such as high blood-sugar levels, increased risk of infection, osteoporosis, water retention, and fragility of the skin. Drugs such as azathioprine and mercaptourine can compromise the immune system and are often effective for Crohn's disease in patients that do not respond to other drugs. These drugs, however, usually need 3 to 6 months before they produce benefits and can cause serious side effects such as allergy, pancreatitis, and low white-blood-cell count.

When Crohn's disease causes the intestine to be obstructed or when abscesses or fistulas do not heal, surgery can be necessary to remove diseased sections of the intestine. Surgery, however, does not cure the disease, and inflammation tends to recur where the intestine is rejoined. In almost half of the cases a second operation is needed. *The Merck Manual of Medical Information* 528-530 (R. Berkow ed., 1997).

Ulcerative colitis is a chronic disease in which the large intestine becomes inflamed and ulcerated, leading to episodes of bloody diarrhea, abdominal cramps, and fever. Ulcerative colitis usually begins between ages 15 and 30; however, a small group of people have their first attack between ages 50 and 70. Unlike Crohn's disease, ulcerative colitis never affects the small intestine and does not affect the full thickness of the intestine. The disease usually begins in the rectum and the sigmoid colon and eventually spreads partially or completely through out the large intestine. The cause of ulcerative colitis is unknown.

Treatment of ulcerative colitis is directed to controlling inflammation, reducing symptoms, and replacing lost fluids and nutrients. Anticholinergic drugs and low

doses of diphenoxylate or loperamide are administered for treating mild diarrhea. For more intense diarrhea higher doses of diphenoxylate or loperamide, or deodorized opium tincture or codeine are administered. Sulfasalazine, olsalazine, prednisone, or mesalamine can be used to reduce inflammation. Azathioprine and mercaptopurine have been used to maintain
5 remissions in ulcerative-colitis patients who would otherwise need long-term corticosteroid treatment. In severe cases of ulcerative colitis the patient is hospitalized and given corticosteroids intravenously. People with severe rectal bleeding can require transfusions and intravenous fluids. If toxic colitis develops and treatments fail, surgery to remove the large intestine can be necessary. Non-emergency surgery can be performed if cancer is diagnosed,
10 precancerous lesions are detected, or unremitting chronic disease would otherwise make the person an invalid or dependent on high doses of corticosteroids. Complete removal of the large intestine and rectum permanently cures ulcerative colitis. *The Merck Manual of Medical Information* 530-532 (R. Berkow ed., 1997) and *Goodman and Gilman's The Pharmacological Basis of Therapeutics* (J. Hardman and L. Limbird eds., 9th ed. 1996).

15 IBS is a disorder of motility of the entire gastrointestinal tract, causing abdominal pain, constipation, and/or diarrhea. IBS affects three-times more women than men. In IBS stimuli such as stress, diet, drugs, hormones, or irritants can cause the gastrointestinal tract to contract abnormally. During an episode of IBS contractions of the gastrointestinal tract become stronger and more frequent, resulting in the rapid transit of food
20 and feces through the small intestine, often leading to diarrhea. Cramps result from the strong contractions of the large intestine and increased sensitivity of pain receptors in the large intestine.

There are two major types of IBS. The first type, spastic-colon type, is commonly triggered by eating, and usually produces periodic constipation and diarrhea with
25 pain. Mucus often appears in the stool. The pain can come in bouts of continuous dull aching pain or cramps, usually in the lower abdomen. The person suffering from spastic-colon type IBS can also experience bloating, gas, nausea, headache, fatigue, depression, anxiety, and difficulty concentrating. The second type of IBS usually produces painless diarrhea or constipation. The diarrhea can begin suddenly and with extreme urgency. Often
30 the diarrhea occurs soon after a meal and can sometimes occur immediately upon awakening.

Treatment of IBS typically involves modification of an IBS-patient's diet. Often it is recommended that an IBS patient avoid beans, cabbage, sorbitol, and fructose. A low-fat, high-fiber diet can also help some IBS patients. Regular physical activity can also help keep the gastrointestinal tract functioning properly. Drugs such as propantheline that slow the function of the gastrointestinal tract are generally not effective for treating IBS. Antidiarrheal drugs, such as diphenoxylate and loperamide, help with diarrhea. *The Merck Manual of Medical Information* 525-526 (R. Berkow ed., 1997).

Many drugs can cause physical and/or psychological addiction. Those most well known types of these drugs include opiates, such as heroin, opium, and morphine; 10 sympathomimetics, including cocaine and amphetamines; sedative-hypnotics, including alcohol, benzodiazepines and barbiturates; and nicotine, which has effects similar to opioids and sympathomimetics. Drug addiction is characterized by a craving or compulsion for taking the drug and an inability to limit its intake. Additionally, drug dependence is associated with drug tolerance, the loss of effect of the drug following repeated 15 administration, and withdrawal, the appearance of physical and behavioral symptoms when the drug is not consumed. Sensitization occurs if repeated administration of a drug leads to an increased response to each dose. Tolerance, sensitization, and withdrawal are phenomena evidencing a change in the central nervous system resulting from continued use of the drug. This change can motivate the addicted individual to continue consuming the drug despite 20 serious social, legal, physical and/or professional consequences. (See, e.g., U.S. Patent No. 6,109,269 to Rise *et al.*).

Certain pharmaceutical agents have been administered for treating addiction. U.S. Patent No. 5,556,838 to Mayer *et al.* discloses the use of nontoxic NMDA-blocking agents co-administered with an addictive substance to prevent the development of tolerance 25 or withdrawal symptoms. U.S. Patent No. 5,574,052 to Rose *et al.* discloses co-administration of an addictive substance with an antagonist to partially block the pharmacological effects of the substance. U.S. Patent No. 5,075,341 to Mendelson *et al.* discloses the use of a mixed opiate agonist/antagonist to treat cocaine and opiate addiction. U.S. Patent No. 5,232,934 to Downs discloses administration of 3-phenoxyypyridine to treat 30 addiction. U.S. Patents No. 5,039,680 and 5,198,459 to Imperato *et al.* disclose using a serotonin antagonist to treat chemical addiction. U.S. Patent No. 5,556,837 to Nestler *et. al.*

discloses infusing BDNF or NT-4 growth factors to inhibit or reverse neurological adaptive changes that correlate with behavioral changes in an addicted individual. U.S. Patent No. 5,762,925 to Sagan discloses implanting encapsulated adrenal medullary cells into an animal's central nervous system to inhibit the development of opioid intolerance. U.S. Patent 5 No. 6,204,284 to Beer *et al.* discloses racemic (\pm)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane for use in the prevention or relief of a withdrawal syndrome resulting from addiction to drugs and for the treatment of chemical dependencies.

Parkinson's disease is a clinical syndrome comprising bradykinesia (slowness and poverty of movement), muscular rigidity, resting tremor (which usually abates during voluntary movement), and an impairment of postural balance leading to disturbance of gait and falling. The features of Parkinson's disease are a loss of pigmented, dopaminergic neurons of the substantia nigra pars compacta and the appearance of intracellular inclusions known as Lewy bodies (*Goodman and Gillman's The Pharmaceutical Basis of Therapeutics* 506 (9th ed. 1996)). Without treatment, Parkinson's disease progresses to a rigid akinetic state in which patients are incapable of caring for themselves. Death frequently results from complications of immobility, including aspiration pneumonia or pulmonary embolism. Drugs commonly used for the treatment of Parkinson's disease include carbidopa/levodopa, pergolide, bromocriptine, selegiline, amantadine, and trihexyphenidyl hydrochloride. There remains, however, a need for drugs useful for the treatment of Parkinson's disease and having an improved therapeutic profile.

Anxiety is a fear, apprehension, or dread of impending danger often accompanied by restlessness, tension, tachycardia, and dyspnea. Other symptoms commonly associated with anxiety include depression, especially accompanied with dysthymic disorder (chronic "neurotic" depression); panic disorder; agoraphobia and other specific phobias; eating disorders; and many personality disorders. Often anxiety is unattached to a clearly identified treatable primary illness. If a primary illness is found, however, it can be desirable to deal with the anxiety at the same time as the primary illness.

Currently, benzodiazepines are the most commonly used anti-anxiety agents for generalized anxiety disorder. Benzodiazepines, however, carry the risk of producing 30 impairment of cognition and skilled motor functions, particularly in the elderly, which can result in confusion, delerium, and falls with fractures. Sedatives are also commonly

prescribed for treating anxiety. The azapirones, such as buspirone, are also used to treat moderate anxiety. The azapirones, however, are less useful for treating severe anxiety accompanied with panic attacks.

Epilepsy is a disorder characterized by the tendency to have recurring seizures.

- 5 The etiology commonly consists of lesions in some part of the cortex, such as a tumor; developmental malformation; or damage due to trauma or stroke. In some cases the etiology is genetic. An epileptic seizure can be triggered by repetitive sounds, flashing lights, video games, or touching certain parts of the body. Epilepsy is typically treated with anti-seizure drugs. In epilepsy cases, where anti-seizure drugs are ineffective, and the defect in the brain
10 is isolated to a small area of the brain, surgical removal of that part of the brain can be helpful in alleviating the seizures. In patients who have several sources for the seizures or who have seizures that spread quickly to all parts of the brain, surgical removal of the nerve fibers that connect the two sides of the brain can be helpful.

Examples of drugs for treating a seizure and epilepsy include carbamazepine,
15 ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, γ -vinyl GABA, acetazolamide, and felbamate. Anti-seizure drugs, however, can have side effects such as drowsiness; hyperactivity; hallucinations; inability to concentrate; central and peripheral nervous system toxicity, such as nystagmus, ataxia, diplopia, and vertigo; gingival hyperplasia; gastrointestinal disturbances such as
20 nausea, vomiting, epigastric pain, and anorexia; endocrine effects such as inhibition of antidiuretic hormone, hyperglycemia, glycosuria, osteomalacia; and hypersensitivity such as scarlatiniform rash, morbilliform rash, Stevens-Johnson syndrome, systemic lupus erythematosus, and hepatic necrosis; and hematological reactions such as red-cell aplasia, agranulocytosis, thrombocytopenia, aplastic anemia, and megaloblastic anemia. *The Merck
25 Manual of Medical Information* 345-350 (R. Berkow ed., 1997).

A seizure is the result of abnormal electrical discharge in the brain. The discharge can involve a small area of the brain and lead to the person only noticing an odd taste or smell or it can involve a large area of the brain and lead to convulsions, *i.e.*, a seizure that causes jerking and spasms of the muscles throughout the body. Convulsions can also
30 result in brief attacks of altered consciousness and loss of consciousness, muscle control, or bladder control. A seizures is often preceded by auras, *i.e.*, unusual sensations of smell, taste,

or vision or an intense feeling that a seizure is about to begin. A seizure typically lasts for about 2 to 5 minutes. When the seizure ends the person can have headache, sore muscles, unusual sensations, confusion, and profound fatigue (postictal state). Usually the person cannot remember what happened during the seizure.

- 5 A stroke or cerebrovascular accident, is the death of brain tissue (cerebral infarction) resulting from the lack of blood flow and insufficient oxygen to the brain. A stroke can be either ischemic or hemorrhagic. In an ischemic stroke, blood supply to the brain is cut off because of atherosclerosis or a blood clot that has blocked a blood vessel. In a hemorrhagic stroke, a blood vessel bursts preventing normal blood flow and allowing blood
- 10 to leak into an area of the brain and destroying it. Most strokes develop rapidly and cause brain damage within minutes. In some cases, however, strokes can continue to worsen for several hours or days. Symptoms of strokes vary depending on what part of the brain is effected. Symptoms include loss or abnormal sensations in an arm or leg or one side of the body, weakness or paralysis of an arm or leg or one side of the body, partial loss of vision or
- 15 hearing, double vision, dizziness, slurred speech, difficulty in thinking of the appropriate word or saying it, inability to recognize parts of the body, unusual movements, loss of bladder control, imbalance, and falling, and fainting. The symptoms can be permanent and can be associated with coma or stupor. Strokes can cause edema or swelling of the brain which can further damage brain tissue. For persons suffering from a stroke, intensive rehabilitation can
- 20 help overcome the disability caused by impairment of brain tissue. Rehabilitation trains other parts of the brain to assume the tasks previously performed by the damaged part.

Examples of drugs for treating strokes include anticoagulants such as heparin, drugs that break up clots such as streptokinase or tissue plasminogen activator, and drugs that reduce swelling such as mannitol or corticosteroids. *The Merck Manual of Medical*

- 25 *Information* 352-355 (R. Berkow ed., 1997).

Pruritus is an unpleasant sensation that prompts scratching. Pruritus can be attributed to dry skin, scabies, dermatitis, herpetiformis, atopic dermatitis, *pruritus vulvae et ani*, miliaria, insect bites, pediculosis, contact dermatitis, drug reactions, urticaria, urticarial eruptions of pregnancy, psoriasis, lichen planus, lichen simplex chronicus, exfoliative

30 dermatitis, folliculitis, bullous pemphigoid, and fiberglass dermatitis. Conventionally,

pruritus is treated by phototherapy with ultraviolet B or PUVA or with therapeutic agents such as naltrexone, nalmefene, danazol, tricyclics, and antidepressants.

Selective antagonists of the metabotropic glutamate receptor 5 ("mGluR5") have been shown to exert analgesic activity in *in vivo* animal models (K. Walker *et al.*, 5 *Neuropharmacology* 40:1-9 (2000) and A. Dogru *et al.*, *Neuroscience Letters*, 292(2):115-118 (2000)).

Selective antagonists of the mGluR5 receptor have also been shown to exert anxiolytic and anti-depressant activity in *in vivo* animal models (E. Tatarczynska *et al.*, *Br. J. Pharmacol.* 132(7):1423-1430 (2001) and P.J.M. Will *et al.*, *Trends in Pharmacological Sciences* 22(7):331-37 (2001)).

Selective antagonists of the mGluR5 receptor have also been shown to exert anti-Parkinson activity *in vivo* (K. J. Ossowska *et al.*, *Neuropharmacology* 41(4):413-20 (2001) and P.J.M. Will *et al.*, *Trends in Pharmacological Sciences* 22(7):331-37 (2001)).

Selective antagonists of the mGluR5 receptor have also been shown to exert 15 anti-dependence activity *in vivo* (C. Chiamulera *et al.*, *Nature Neuroscience* 4(9):873-74 (2001)).

U.S. Patent No. 6,150,129 to Cook *et al.* describes a class of dinitrogen heterocycles useful as antibiotics.

U.S. Patent No. 5,529,998 to Habich *et al.* describes a class of benzooxazolyl- 20 and benzothiazolylloxazolidones useful as antibacterials.

International publication no. WO 01/57008 describes a class of 2-benzothiazolyl urea derivatives useful as inhibitors of serine/threonine and tyrosine kinases.

International publication no. WO 02/08221 describes aryl piperazine compounds useful for treating chronic and acute pain conditions, itch, and urinary 25 incontinence.

International publication no. WO 99/37304 describes substituted oxoazaheterocyclic compounds useful for inhibiting factor Xa.

International publication no. WO 00/59510 describes aminopyrimidines useful as sorbitol dehydrogenase inhibitors.

Japanese patent application no. 11-199573 to Kiyoshi *et al.* describes benzothiazole derivatives that are neuronal 5HT3 receptor agonists in the intestinal canal nervous system and useful for treating digestive disorders and pancreatic insufficiency.

German patent application no 199 34 799 to Rainer *et al.* describes a chiral-
5 smectic liquid crystal mixture containing compounds with 2 linked (hetero)aromatic rings or compounds with 3 linked (hetero)aromatic rings.

M. Chu-Moyer *et al.*, *J. Med. Chem.* 45:511-528 (2002) describes heterocycle-substituted piperazino-pyrimidines useful as sorbitol dehydrogenase inhibitors.

B.G. Khadse *et al.*, *Bull. Haff. Instt.* 1(3):27-32 (1975) describes 2-(N⁴-
10 substituted-N¹-piperazinyl) pyrido(3,2-d)thiazoles and 5-nitro-2-(N⁴-substituted-N¹-piperazinyl)benzthiazoles useful as anthelmintic agents.

There remains, however, a clear need in the art for new drugs useful for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive
15 disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression.

Citation of any reference in Section 2 of this application is not to be construed as an admission that such reference is prior art to the present application.


20

3. SUMMARY OF THE INVENTION

The present invention encompasses compounds having the formula (Ia):

25

30




(Ia)


and pharmaceutically acceptable salts thereof, wherein

Ar₁ is

5



10



R₁ is -Cl, -Br, -I, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃,
15 -CH(halo)₂, or -CH₂(halo);

each R² is independently:

(a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

25

(c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;

30

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

C_{14})bicycloalkenyl, $-(C_8-C_{14})$ tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$ aryl or -(5- to 10-

5 membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R_4 is -H or $-(C_1-C_6)$ alkyl;

each R_5 is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R_7)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

10 each R_6 is independently $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl, $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, $-(C_3-C_5)$ heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R_7)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R_7 is independently -H, $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl,

15 $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, $-(C_3-C_5)$ heterocycle, -C(halo)₃, -CH₂(halo), or -CH(halo)₂;

R_8 and R_9 are each independently -H, $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl, $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R_7)₂,

20 -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each -halo is -F, -Cl, -Br, -I or -I;


n is an integer ranging from 0 to 3;

p is an integer ranging from 0 to 2;

25 m is 0 or 1; and

x is 0 or 1.

The present invention encompasses compounds having the formula (Ib):




5

(Ib)


and pharmaceutically acceptable salts thereof, wherein

Ar_1 is



15

A is



20

R_1 is -H, -halo, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

25

each R^2 is independently:

- (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-heterocycle, each of which is unsubstituted or substituted with one or more

(c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

- 5 (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
- (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more

10 R₅ groups; or

- (c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₄ is -H or -(C₁-C₆)alkyl;

15 each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇,

-NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇,

20 -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl,

25 -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each -halo is -F, -Cl, -Br, or -I;

30 p is an integer ranging from 0 to 2;


m is 0 or 1; and

x is 0 or 1.

The present invention encompasses compounds having the formula (IIa):

5

10





(IIa)

and pharmaceutically acceptable salts thereof, wherein

15

Ar₁ is



, or ;

20

R₁ is -Cl, -Br, -I, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R² is independently:

(a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;

25 (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₃-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

- 5 (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
 (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more
 10 R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

- each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇,
 15 -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;
 each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;
 20 each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂,
 25 -CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

R₁₀ is -H or -(C₁-C₄)alkyl;


each -halo is -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 3;

30 p is an integer ranging from 0 to 2; and

m is 0 or 1.

The present invention encompasses compounds having the formula (IIb):




(IIb)

and pharmaceutically acceptable salts thereof, wherein


Ar₁ is

15



A is

20



R₁ is -H, -halo, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃,

25 -CH(halo)₂, or -CH₂(halo);

each R² is independently:

(a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-

C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-

30 C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-

membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

- (c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆

5 groups;

each R₃ is independently:

- (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
- (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

- (c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆

15 groups;

R₄ is -H or -(C₁-C₆)alkyl;

each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

20 -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

25 -CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or

30 -S(O)₂R₇;


R₁₀ is -H or -(C₁-C₄)alkyl;

each -halo is -F, -Cl, -Br, or -I;
 p is an integer ranging from 0 to 2;
 m is 0 or 1; and
 x is 0 or 1.

5

The present invention encompasses compounds having the formula (IIIa):

10




15

(IIIa)

and pharmaceutically acceptable salts thereof, wherein


Ar₁ is

20



25

A is



R₁ is -Cl, -Br, -I, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

30

each R² is independently:

(a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;

(b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$ cycloalkyl, $-(C_8-C_{14})$ bicycloalkyl, $-(C_8-C_{14})$ tricycloalkyl, $-(C_5-C_{10})$ cycloalkenyl, $-(C_8-C_{14})$ bicycloalkenyl, $-(C_8-C_{14})$ tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more

5 R₅ groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$ aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

10 (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
 (b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$ cycloalkyl, $-(C_8-C_{14})$ bicycloalkyl, $-(C_8-C_{14})$ tricycloalkyl, $-(C_5-C_{10})$ cycloalkenyl, $-(C_8-C_{14})$ bicycloalkenyl, $-(C_8-C_{14})$ tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more

15 R₅ groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$ aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₄ is -H or $-(C_1-C_6)$ alkyl;

20 each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl, $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇,

25 -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl, $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl,

30 $-(C_2-C_6)$ alkynyl, $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂,

-CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each -halo is -F, -Cl, -Br, -I or -I;

5 n is an integer ranging from 0 to 3;


p is an integer ranging from 0 to 2;

m is 0 or 1; and

x is 0 or 1.

The present invention encompasses compounds having the formula (IIIb):

10




15

(IIIb)

and pharmaceutically acceptable salts thereof, wherein


Ar₁ is

25



A is

30



R_1 is -H, -halo, $-(C_1-C_6)$ alkyl, $-NO_2$, $-CN$, $-OH$, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)_2$;

each R^2 is independently:

(a) -halo, $-CN$, $-OH$, $-O(C_1-C_6)$ alkyl, $-NO_2$, or $-NH_2$;

5 (b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$ cycloalkyl, $-(C_8-C_{14})$ bicycloalkyl, $-(C_8-C_{14})$ tricycloalkyl, $-(C_5-C_{10})$ cycloalkenyl, $-(C_8-C_{14})$ bicycloalkenyl, $-(C_8-C_{14})$ tricycloalkenyl, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, or (C_{14}) aryl each of which is unsubstituted

10 or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, $-CN$, $-OH$, $-O(C_1-C_6)$ alkyl, $-NO_2$, or $-NH_2$;

15 (b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$ cycloalkyl, $-(C_8-C_{14})$ bicycloalkyl, $-(C_8-C_{14})$ tricycloalkyl, $-(C_5-C_{10})$ cycloalkenyl, $-(C_8-C_{14})$ bicycloalkenyl, $-(C_8-C_{14})$ tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, (C_{14}) aryl or -(5- to 10-

membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6

20 groups;

R_4 is -H or (C_1-C_6) alkyl;

each R_5 is independently $-CN$, $-OH$, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH=NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

each R_6 is independently $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl,

25 $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, $-(C_3-C_5)$ heterocycle, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)_2$, $-CN$, $-OH$, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH=NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

each R_7 is independently -H, $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl, $-(C_2-C_6)$ alkynyl,

$-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, $-(C_3-C_5)$ heterocycle, $-C(halo)_3$,

30 $-CH_2(halo)_2$, or $-CH(halo)_2$;

R_8 and R_9 are each independently -H, $-(C_1-C_6)$ alkyl, $-(C_2-C_6)$ alkenyl,

$-(C_2-C_6)$ alkynyl, $-(C_3-C_8)$ cycloalkyl, $-(C_5-C_8)$ cycloalkenyl, -phenyl, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, $-OC(halo)_3$, $-OCH(halo)_2$, $-OCH_2(halo)$, $-CN$, $-OH$, $-halo$, $-N_3$, $-N(R_7)_2$, $-CH=NR_7$, $-NR_7OH$, $-OR_7$, $-COR_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

5 each $-halo$ is $-F$, $-Cl$, $-Br$, or $-I$;


p is an integer ranging from 0 to 2;

m is 0 or 1; and

x is 0 or 1.

The present invention also encompasses compounds having the formula (IVa):

10




15

(IVa)

and pharmaceutically acceptable salts thereof, wherein

Ar₁ is

20




or

25

Ar₂ is

30



R₁ is -halo, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R² is independently:

- 5 (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
 (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more

10 R₅ groups; or

- (c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₃ is -H or -CH₃:

- 15 each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;
 each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇,
 20 -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;
 each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃, -CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl,


- 25 -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each -halo is -F, -Cl, -Br, or -I;

30 n is an integer ranging from 0 to 3; and

p is an integer ranging from 0 to 2.


The present invention also encompasses compounds having the formula (IVb):




(IVb)

and pharmaceutically acceptable salts thereof, wherein

Ar₁ is




Ar₂ is



25

A is



30

R₁ is -halo, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃,

-CH(halo)₂, or -CH₂(halo);

each R² is independently:

- (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
- (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-

5 C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

- (c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-

10 membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₃ is -CH₃;

R₄ is -H or -(C₁-C₆)alkyl;

each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇,

15 -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

-(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

-CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇,

-COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

20 each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

-(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

-CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl,

-(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂,

25 -CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂,

-CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or

-S(O)₂R₇;

each -halo is -F, -Cl, -Br, or -I;


n is an integer ranging from 0 to 3;

30 p is an integer ranging from 0 to 2; and

x is 0 or 1.

The present invention also encompasses compounds having the formula (V):

5




(V)

10 and pharmaceutically acceptable salts thereof, wherein


Ar₁ is

15



Ar₂ is

20



R₁ is -halo, -(C₁-C₆)alkyl, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃,

25 -CH(halo)₂, or -CH₂(halo);

each R² is independently:

- (a) -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂;
- (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-

30 C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-

membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-

membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆

5 groups;

R₃ is -H or -CH₃:

each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇,

-NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

10 -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

-CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇,

-COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

-(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

15 -CH₂(halo), or -CH(halo)₂;

R₈ and R₉ are each independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl,

-(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂,

-CH₂(halo), -OC(halo)₃, -OCH(halo)₂, -OCH₂(halo), -CN, -OH, -halo, -N₃, -N(R₇)₂,

-CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or

20 -S(O)₂R₇;

each -halo is -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 3; and

p is an integer ranging from 0 to 2.

A compound of formula (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IVa), (IVb), and

25 (V) or a pharmaceutically acceptable salt thereof (a "Benzoazolylpiperazine Compound") is

useful for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder,

Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition,

psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's

chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or

30 depression in an animal.

The invention also relates to compositions comprising an effective amount of a Benzoazolylpiperazine Compound and a pharmaceutically acceptable carrier or excipient. The compositions are useful for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal.

5 The invention further relates to methods for treating pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound.

10 The invention further relates to methods for preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound.

15 The invention still further relates to methods for inhibiting Vanilloid Receptor 1 ("VR1") function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of a Benzoazolylpiperazine Compound.

20 The invention still further relates to methods for inhibiting mGluR5 function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a Benzoazolylpiperazine Compound.


25 The invention still further relates to methods for inhibiting metabotropic glutamate receptor 1 ("mGluR1") function in a cell, comprising contacting a cell capable of expressing mGluR1 with an effective amount of a Benzoazolylpiperazine Compound.

30 The invention still further relates to a method for preparing a composition comprising the step of admixing a Benzoazolylpiperazine Compound and a pharmaceutically acceptable carrier or excipient.


The invention still further relates to a kit comprising a container containing an effective amount of a Benzoazolylpiperazine Compound.

The present invention still further relates to a compound selected from the group consisting of


5




10



20










25



and pharmaceutically acceptable salts thereof.


The present invention still further relates to a compound selected from the group consisting of





and pharmaceutically acceptable salts thereof.

The present invention still further relates to a compound selected from the group consisting of



and pharmaceutically acceptable salts thereof.

15 The present invention can be understood more fully by reference to the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention.

4. DETAILED DESCRIPTION OF THE INVENTION


4.1 The Compounds of Formula (Ia)

As stated above, the present invention encompasses compounds of Formula

(Ia)

5

10



(Ia)

15 and pharmaceutically acceptable salts thereof, where Ar₁, R₃, R₈, R₉, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (Ia).

In one embodiment, Ar₁ is a pyridyl group.

In another embodiment, Ar₁ is a pyrimidinyl group.

In another embodiment, x is 1 and A is -C(O)-N(R₄)-.

20 In another embodiment, x is 1 and A is -C(S)-N(R₄)-.

In another embodiment x is 0.

In another embodiment, n or p is 0.

In another embodiment, n or p is 1.

In another embodiment, m is 0.

25 In another embodiment, m is 1.

In another embodiment, R₄ is -H.

In another embodiment, R₄ is -(C₁-C₆)alkyl.

In another embodiment, Ar₁ is a pyridyl group, x is 1, and A is -C(O)N(R₄)-.

In another embodiment, Ar₁ is a pyridyl group, x is 1, and A is -C(S)N(R₄)-.

30 In another embodiment, Ar₁ is a pyrimidinyl group, x is 1, and A is -

C(O)N(R₄)-.

In another embodiment, Ar₁ is a pyrimidinyl group, x is 1, and A is -

C(S)N(R₄)-.

In another embodiment, R₁ is -Cl.

In another embodiment, R₁ is -Br.

5 In another embodiment, R₁ is -I.

In another embodiment, R₁ is -(C₁-C₆)alkyl.

In another embodiment, R₁ is -CH₃.

In another embodiment, R₁ is -NO₂.

In another embodiment, R₁ is -CN.

10 In another embodiment, R₁ is -OH.

In another embodiment, R₁ is -OCH₃.

In another embodiment, R₁ is -NH₂.

In another embodiment, R₁ is -C(halo)₃.

In another embodiment, R₁ is -CH(halo)₂.

15 In another embodiment, R₁ is -CH₂(halo).

In another embodiment, n and p are 1 and R₂ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.

In another embodiment, n and p are 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.

20 In another embodiment, n and p are 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or 25 more R₆ groups;

In another embodiment, m is 1 and R₃ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.

In another embodiment, m is 1 and R₃ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-

membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.

In another embodiment, m is 1 and R₃ is -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

In another embodiment, R₈ and R₉ are each independently -H, -halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₁ is -Cl. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₁ is -Cl. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₁ is -Cl. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₁ is -Cl. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is

-C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is
5 -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

15 In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

20 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In
another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

25 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In
another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

30 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is
-C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

5 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

15 In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

20 In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

25 In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

5 In another embodiment, n, p, and m are 0; R₁ is R₁ is -Cl, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -CH₃.

In another embodiment, n is 0, Ar₁ is -2-(3-nitropyridyl)-, m is 0, x is 0, and R₈ and R₉ are -H.

15 In another embodiment, n is 0, Ar₁ is -2-(3-chloropyridyl)-, x is 1, A is -C(S)-N(R₄)-, m is 1, R₃ is -CH₃, R₃ is attached to the carbon atom adjacent to the nitrogen attached to the -C(SO)-N(R₄)- group, the carbon atom to which the R₃ group is attached has the R configuration, R₈ is -H, and R₉ is -CH₃.

20 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is

-Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. . In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-; R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In 10 another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is 15 -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S 25 configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 15 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 25 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I, x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

15 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

25 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the

30 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 10 attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen

attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-
5 N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-
10 N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-
15 N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-
20 N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S
25 configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-
N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In
30

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 15 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 25 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 0; R₄ is -H; and R₈ and R₉ are -H.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

15 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

20 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

25 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

5 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

15 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

20 In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

25 In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

30 In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is

-H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0, R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; and R₈ 5 and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is 10 -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0, R₁ is -CF₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is 15 -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; x is 0; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; 25 R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or, -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

5 In another embodiment, n, p, and m are 0; R₁ is -CH₃; x is 0; R₄ is -H; R₈ is -CH₃; and R₉ is -CH₃.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another 20 embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another 25 embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another 30

embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is 5 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is 15 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is 20 -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is 25 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is 30 -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzothiazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 benzothiazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 25 benzothiazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 30 benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

5 benzothiazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

10 benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

15 benzothiazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

benzothiazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is 5 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is 10 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is 15 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is 20 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is 25 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is 30 -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another

embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

benzothiazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or, -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the

R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group,
5 R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group,
10 R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to
15 the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is
20 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -Cl, -Br, or
25 -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen

attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 5 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -CH₃, 10 -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In 10 another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the 20 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In 5 another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another 15 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 25 benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the 30 benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is

1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is attached is in the R configuration.


In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is attached is in the S configuration.

4.2 The Compounds of Formula (Ib)

The present invention also encompasses compounds of formula (Ib):

15



20

(Ib)

and pharmaceutically acceptable salts thereof, where Ar₁, R₃, R₈, R₉, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (Ib).

30

In one embodiment, Ar₁ is a pyrazinyl group.

In another embodiment, Ar₁ is a pyridazinyl group.

In another embodiment, Ar₁ is a thiazanyl group.

In another embodiment, x is 1 and A is -C(O)-N(R₄)-.

In another embodiment, x is 1 and A is -C(S)-N(R₄)-.

- In another embodiment x is 0.
- In another embodiment, p is 0.
- In another embodiment, p is 1.
- In another embodiment, m is 0.
- 5 In another embodiment, m is 1.
- In another embodiment, R₄ is -H.
- In another embodiment, R₄ is -(C₁-C₆)alkyl.
- In another embodiment, Ar₁ is a pyrazinyl group, x is 1, and A is -C(O)N(R₄)-.
- In another embodiment, Ar₁ is a pyrazinyl group, x is 1, and A is -C(S)N(R₄)-.
- 10 In another embodiment, Ar₁ is a pyridazinyl group, x is 1, and A is -C(O)N(R₄)-.
- In another embodiment, Ar₁ is a pyridazinyl group, x is 1, and A is -C(S)N(R₄)-.
- In another embodiment, Ar₁ is a thiazanyl group, x is 1, and A is -C(O)N(R₄)-.
- 15 In another embodiment, Ar₁ is a thiazanyl group, x is 1, and A is -C(S)N(R₄)-.
- In another embodiment, R₁ is -H.
- In another embodiment, R₁ is -Cl.
- In another embodiment, R₁ is -Br.
- In another embodiment, R₁ is -I.
- 20 In another embodiment, R₁ is -F.
- In another embodiment, R₁ is -(C₁-C₆)alkyl.
- In another embodiment, R₁ is -CH₃.
- In another embodiment, R₁ is -NO₂.
- In another embodiment, R₁ is -CN.
- 25 In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- In another embodiment, R₁ is -NH₂.
- In another embodiment, R₁ is -C(halo)₃.
- In another embodiment, R₁ is -CH(halo)₂.
- 30 In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, p is 1 and R₂ is -halo, -CN, -OH, -O(C₁-C₆)alkyl,

-NO₂, or -NH₂.

In another embodiment, p is 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.

In another embodiment, p is 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

10 In another embodiment, m is 1 and R₃ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.

In another embodiment, m is 1 and R₃ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.

In another embodiment, m is 1 and R₃ is -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

20 In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ or R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

25 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

5 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

10 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

15 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

20 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

25 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

30 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, 10 R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

15 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, 20 R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

25 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, 30 R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

5 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

20 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 25 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 10 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 15 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 20 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 25 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 30 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 10 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 15 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 20 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 25 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ 30 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 10 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another 30 embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 25 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ 5 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ 10 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ 15 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ 20 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ 25 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ 30 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- 5 N(R₄)- group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, and R₈ and R₉ are -H.

10 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

20 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

25 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

5 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

20 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

10 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

15 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

25 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

10 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is

-Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃

5 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 20 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 25 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 30 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃

5 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which

10 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃

15 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which

20 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃

25 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to

30 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 5 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ 20 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, 30 R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 5 group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 10 group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 15 group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 20 group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 25 group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 30 group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the

R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 5 group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl 10 group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 15 and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In one embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl

group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃

group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ 5 is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ 10 is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ 15 is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ 20 is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the 25 nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 30 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 benzothiazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the 25 carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon 30 atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the

carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the
5 carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S configuration.

10 In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzothiazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S
15 configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or a thiazanyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or a
20 thiazanyl group and the carbon to which the R₃ group is attached is in the R configuration. ;

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group
25 and the carbon to which the R₃ group is attached is in the R configuration.


In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or
30 thiazanyl group and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group 5 and the carbon to which the R₃ group is attached is in the S configuration.

The present invention also encompasses compounds of formula (IIa):

4.3 The Compounds of Formula (IIa)

10



15

(IIa)

and pharmaceutically acceptable salts thereof, where Ar₁, R₃, R₈, R₉, R₁₀ and m, are defined 20 above for the Benzoazolylpiperazine Compounds of formula (IIa).

In one embodiment, Ar₁ is a pyridyl group.

In another embodiment, Ar₁ is a pyrimidinyl group.

In another embodiment, Ar₁ is a pyrazinyl group.

In another embodiment, n or p is 0.

25

In another embodiment, n or p is 1.

In another embodiment, m is 0.

In another embodiment, m is 1.

In another embodiment, R₁₀ is -H.

In another embodiment, R₁₀ is -(C₁-C₄)alkyl.

30

In another embodiment, R₁₀ is -CH₃.

In another embodiment, R₁ is -Cl.

- In another embodiment, R₁ is -Br.
- In another embodiment, R₁ is -I.
- In another embodiment, R₁ is -(C₁-C₆)alkyl.
- In another embodiment, R₁ is -CH₃.
- 5 In another embodiment, R₁ is -NO₂.
- In another embodiment, R₁ is -CN.
- In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- In another embodiment, R₁ is -NH₂.
- 10 In another embodiment, R₁ is -C(halo)₃.
- In another embodiment, R₁ is -CH(halo)₂.
- In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, n and p are 1 and R₂ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.
- 15 In another embodiment, n and p are 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.
- 20 In another embodiment, n and p are 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;
- In another embodiment, m is 1 and R₃ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.
- 25 In another embodiment, m is 1 and R₃ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.

In another embodiment, m is 1 and R₃ is -phenyl, -naphthyl, -(C₁₄)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-

5 C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ or R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, R₄ is -H; and R₈ and R₉ are
10 -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -halo H; and R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br.

In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -halo; and
15 R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another
embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -CH₃. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another
embodiment, R₉ is -F.

20 In another embodiment, n, p, and m are 0; R₁ is -Cl, R₄ is -H; R₈ is -H; and R₉ is -CH₃. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another
embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -CH₃; and R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In
25 another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, R₄ is -H; R₈ is -CH₃; and
R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another
embodiment, R₉ is -F.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -CF₃. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another
embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -H; and R₉ is -CF₃. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -CF₃; and R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -CF₃; and R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In 15 another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -OCH₂CH₃; 20 and R₉ is -H. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -H; and R₉ 25 is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, Br, or -I; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl, Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, Br, or -I; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

5 In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, Br, or -I; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

15 In another embodiment, n, p, and m are 0, R₁ is -CH₃, R₄ is -H, and R₈ and R₉ are -H.

20 In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

25 In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

30 In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

5 In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

10 In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

15 In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

20 In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -CF₃; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

25 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -Cl; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

5 In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -CH₃; R₄ is -H; R₈ is -CH₃; and R₉ is -CH₃.

In another embodiment, n is 0, Ar₁ is -2-(3-chloropyridyl)-, m is 1, R₃ is -CH₃
10 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, the carbon atom to which the R₃ group is attached has the R configuration, R₁₀ is -H, R₈ is methyl, and R₉ is *iso*-propyl.

In another embodiment, n is 0, Ar₁ is -2-(3-chloropyridyl)-, m is 1, R₃ is -CH₃
and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole
15 group, the carbon atom to which the R₃ group is attached has the R configuration, R₁₀ is -H, R₈ is *iso*-propyl, and R₉ is methyl.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.
25

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another 30 embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 10 the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 20 the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 30 the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -benzimidazole group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -benzimidazole group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazole group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazole group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazole group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ 25 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazole group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to 30 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ 10 group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ 15 group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ 20 group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ 25 group is attached has the R configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 30 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ 10 group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, 20 R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 25 group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 30 group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃

group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 5 group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 10 group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 15 group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 20 group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole 25 group; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₄ 30 is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃

group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -Cl, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazole group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group n is 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

5 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
10 benzoimidazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -Cl, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
15 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
20 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
25 benzimidazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
30 benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -Cl, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group; p is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group; p is 0; m is 1; R₁ is -Cl, -Br, or -I; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -Cl, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another 15 embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another embodiment, 20 m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another 25 embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group. In another embodiment, 30 m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to

the -C(O)-N(R₄)- or the benzothiazolyl group and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or 5 pyrazinyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl 10 group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R₃ group is attached is in the R configuration.


In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or 15 pyrazinyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl 20 group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group, pyrimidinyl group, or pyrazinyl group and the carbon to which the R₃ group is attached is in the S configuration.

4.4 The Compounds of Formula (IIb)

25 The present invention also encompasses compounds of formula (IIb):

5



10

(IIb)

and pharmaceutically acceptable salts thereof, where Ar₁, R₃, R₈, R₉, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (Iib).

In one embodiment, Ar₁ is a pyridazinyl group.

15 In another embodiment, Ar₁ is a thiazanyl group.

In another embodiment, x is 1 and A is -C(O)-N(R₄)-.

In another embodiment, x is 1 and A is -C(S)-N(R₄)-.

In another embodiment x is 0.

In another embodiment, x is 1.

20 In another embodiment p is 0.

In another embodiment, p is 1.

In another embodiment m is 0.

In another embodiment, m is 1.

In another embodiment, R₄ is -H.

25 In another embodiment, R₄ is -(C₁-C₆)alkyl.

In another embodiment, R₁₀ is -H.

In another embodiment, R₁₀ is -(C₁-C₄)alkyl.

In another embodiment, R₁₀ is -CH₃.

In another embodiment, Ar₁ is a pyrazinyl group, x is 1, and A is -C(O)N(R₄)-.

30 In another embodiment, Ar₁ is a pyrazinyl group, x is 1, and A is -C(S)N(R₄)-.

In another embodiment, Ar₁ is a thiazanyl group, x is 1, and A is -C(O)N(R₄)-.

- In another embodiment, Ar₁ is a thiazanyl group, x is 1, and A is -C(S)N(R₄)-.
- In another embodiment, R₁ is -H.
- In another embodiment, R₁ is -Cl.
- In another embodiment, R₁ is -Br.
- 5 In another embodiment, R₁ is -I.
- In another embodiment, R₁ is -F.
- In another embodiment, R₁ is -(C₁-C₆)alkyl.
- In another embodiment, R₁ is -CH₃.
- In another embodiment, R₁ is -NO₂.
- 10 In another embodiment, R₁ is -CN.
- In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- In another embodiment, R₁ is -NH₂.
- In another embodiment, R₁ is -C(halo)₃.
- 15 In another embodiment, R₁ is -CH(halo)₂.
- In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, p is 1 and R₂ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.
- In another embodiment, p is 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.
- 20 In another embodiment, p is 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;
- 25 In another embodiment, m is 1 and R₃ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.
- In another embodiment, m is 1 and R₃ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-

membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.

In another embodiment, m is 1 and R₃ is -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ or R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

5 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

15 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

20 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

30 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

15 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

20 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

25 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -tert-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl.

5 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

15 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the
10 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon
15 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to
20 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to
25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to
30 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another 30 embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 25 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ 10 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 20 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 25 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 30 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 10 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 20 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

5 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

10 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

25 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

5 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, 10 and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

15 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, 30 and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

5 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

15 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

20 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

30 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl

group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and 5 is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ 10 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is

-Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ 5 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and 10 is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ 15 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and 20 is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ 25 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and 30 is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is

attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 5 group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 10 group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 15 group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 20 group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 25 group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, 30 R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃

group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 5 group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl 10 group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ 15 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl

group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ 5 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ 10 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ 15 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 20 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 25 and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl

group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl

group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the

R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoimidazolyl group,
5 R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the 10 nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x 15 is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -halo, x 20 is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -Cl, x 25 is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x 30 is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 10 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -halo, x is 15 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -Cl, x is 20 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 25 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 25 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 30 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 benzoimidazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the 20 benzoimidazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzoimidazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon 25 atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzoimidazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzoimidazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

30 In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the

benzimidazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzimidazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S configuration.

5 In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzimidazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzimidazolyl group when x is 0 and the carbon to which the R₃ group is attached is
10 in the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to
15 which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to which the R₃ group is
20 attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to
25 which the R₃ group is attached is in the S configuration.


In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridazinyl group or thiazanyl group and the carbon to which the R₃ group is
30 attached is in the S configuration.

4.5 The Compounds of Formula (IIIa)

The present invention encompasses compounds of Formula (IIIa)

5

10



(IIIa)

and pharmaceutically acceptable salts thereof, where Ar₁, R₃, R₈, R₉, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (IIIa).

20

In one embodiment, Ar₁ is a pyridyl group.

In another embodiment, Ar₁ is a pyrimidinyl group.

In another embodiment, x is 1 and A is -C(O)-N(R₄)-.

In another embodiment, x is 1 and A is -C(S)-N(R₄)-.

In another embodiment x is 0.

In another embodiment x is 1.

In another embodiment n or p is 0.

In another embodiment n or p is 1.

In another embodiment m is 0.

25

In another embodiment m is 1.

In another embodiment, Ar₁ is a pyridyl group, x is 1, and A is -C(O)N(R₄)-.

In another embodiment, Ar₁ is a pyridyl group, x is 1, and A is -C(S)N(R₄)-.

In another embodiment, Ar₁ is a pyrimidinyl group, x is 1, and A is -C(O)N(R₄)-.

30

In another embodiment, Ar₁ is a pyrimidinyl group, x is 1, and A is -C(S)N(R₄)-.

- In another embodiment, R₁ is -Cl.
- In another embodiment, R₁ is -Br.
- In another embodiment, R₁ is -I.
- In another embodiment, R₁ is -(C₁-C₆)alkyl.
- 5 In another embodiment, R₁ is -CH₃.
- In another embodiment, R₁ is -NO₂.
- In another embodiment, R₁ is -CN.
- In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- 10 In another embodiment, R₁ is -NH₂.
- In another embodiment, R₁ is -C(halo)₃.
- In another embodiment, R₁ is -CH(halo)₂.
- In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, n and p are 1 and R₂ is -halo, -CN, -OH, -O(C₁-
- 15 C₆)alkyl, -NO₂, or -NH₂.
- In another embodiment, n and p are 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is
- 20 unsubstituted or substituted with one or more R₅ groups.
- In another embodiment, n and p are 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;
- In another embodiment, m is 1 and R₃ is -halo, -CN, -OH, -O(C₁-C₆)alkyl,
- 25 -NO₂, or -NH₂.
- In another embodiment, m is 1 and R₃ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is
- 30 unsubstituted or substituted with one or more R₅ groups.

In another embodiment, m is 1 and R₃ is -phenyl, -naphthyl, -(C₁₄)aryl or -(5-to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

In another embodiment, R₄ is -H.

5 In another embodiment, R₄ is -(C₁-C₆)alkyl.

In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ or R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; and R₈ and R₉ are -H.

15 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

20 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

25 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H, R₈ is -H; and R₉ is -CF₃.

5 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

15 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

20 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

25 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

30 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is

-C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is

5 -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

10 In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In 15 another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is 25 -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

30 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

5 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

10 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

In another embodiment, n is 0, Ar₁ is -2-(3-nitropyridyl)-, m is 0, x is 0, and R₈ and R₉ are -H.

15 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, n and p are 0; m is 1, R₁ is -Cl; x is 1, A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 10 attached to the -C(O)-N(R₄)- group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In 20 another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the 25 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the 30 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 15 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 25 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is

-C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 10 attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 15 attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 20 attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 25 attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 30 attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 15 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 25 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

5 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

15 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another

25 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the

30 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; and R₈ and R₉ are -H.

5 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In 10 another embodiment, R₉ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, x is 0; R₄ is -H; R₈ is 15 -halo; and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; 20 and R₉ is -CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -CH₃; and R₉ is -H.

25 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -CF₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; 30 R₈ is -CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is

-CF₃; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

5 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -OCH₂CH₃; and R₉ is -H.

10 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 0; R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 0; R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

15 In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 0; R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0; R₁ is -CH₃, x is 0; R₄ is -H, R₈ is -H, and R₉ is -CH₃.

20 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

25 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

30 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

5 In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

10 In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

15 In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, n, p, and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

20 In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, n, p, and m are 0; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

25 In another embodiment, n, p, and m are 0; R₁ is -Cl; x is 0; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

30 In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, n, p, and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is

-CH₃, and R₉ is -CH₃.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1, R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another 15 embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, n and p are 0; m is 1, R₁ is -Cl; x is 0; R₄ is -H; R₃ is

-CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1, R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 20 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 25 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₄ is -H; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 30 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₄ is -H; R₃ is

-CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the 20 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to 30 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 20 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0; m is 1; R₁ is -Cl; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 30 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the S configuration.

In another embodiment, n and p are 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R 15 configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

20 In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -CH₃, -Cl, -Br, -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 1; A is -C(O)-N(R₄)-; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

25 In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

30 In another embodiment, Ar₁ is a pyridyl group; n is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to

the benzooxazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the R configuration.

In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -CH₃, -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group; p is 0; m is 1; R₁ is -Cl, -Br, or -I; x is 0; R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group; R₄ is -H; R₈ is -H; and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group and 5 the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group and the carbon to which the 10 R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group and 15 the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- or the benzooxazolyl group and the carbon to which the 20 R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to 25 which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is 30 attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is attached is in the S configuration.


In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyridyl group or pyrimidinyl group and the carbon to which the R₃ group is attached is in the S configuration.

4.6 The Compounds of Formula (IIIb)

The present invention also encompasses compounds of formula (IIIb):

15

20



(IIIb)

and pharmaceutically acceptable salts thereof, where Ar₁, R₃, R₈, R₉, A, x, and m, are defined above for the Benzoazolylpiperazine Compounds of formula (IIIb).

In one embodiment, Ar₁ is a pyrazinyl group.

In another embodiment, Ar₁ is a pyridazinyl group.

In another embodiment, Ar₁ is a thiazanyl group.

In another embodiment, x is 1 and A is -C(O)-N(R₄)-.

30 In another embodiment, x is 1 and A is -C(S)-N(R₄)-.

In another embodiment x is 0.

- In another embodiment, x is 1.
- In another embodiment, p is 0.
- In another embodiment, p is 1.
- In another embodiment, m is 0.
- 5 In another embodiment, m is 1.
- In another embodiment, Ar₁ is a pyrazinyl group, x is 1, and A is -C(O)N(R₄)-.
- In another embodiment, Ar₁ is a pyrazinyl group, x is 1, and A is -C(S)N(R₄)-.
- In another embodiment, Ar₁ is a pyridazinyl group, x is 1, and A is
-C(O)N(R₄)-.
- 10 In another embodiment, Ar₁ is a pyridazinyl group, x is 1, and A is
-C(S)N(R₄)-.
- In another embodiment, Ar₁ is a thiazanyl group, x is 1, and A is -C(O)N(R₄)-.
- In another embodiment, Ar₁ is a thiazanyl group, x is 1, and A is -C(S)N(R₄)-.
- In another embodiment, R₁ is -H.
- 15 In another embodiment, R₁ is -Cl.
- In another embodiment, R₁ is -Br.
- In another embodiment, R₁ is -I.
- In another embodiment, R₁ is -F.
- In another embodiment, R₁ is -(C₁-C₆)alkyl.
- 20 In another embodiment, R₁ is -CH₃.
- In another embodiment, R₁ is -NO₂.
- In another embodiment, R₁ is -CN.
- In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- 25 In another embodiment, R₁ is -NH₂.
- In another embodiment, R₁ is -C(halo)₃.
- In another embodiment, R₁ is -CH(halo)₂.
- In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, p is 1 and R₂ is -halo, -CN, -OH, -O(C₁-C₆)alkyl,
30 -NO₂, or -NH₂.

In another embodiment, p is 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is

5 unsubstituted or substituted with one or more R₅ groups.

In another embodiment, p is 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

In another embodiment, m is 1 and R₃ is -halo, -CN, -OH, -O(C₁-C₆)alkyl,
10 -NO₂, or -NH₂.

In another embodiment, m is 1 and R₃ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is
15 unsubstituted or substituted with one or more R₅ groups.

In another embodiment, m is 1 and R₃ is -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups.

In another embodiment, R₄ is -H.

20 In another embodiment, R₄ is -(C₁-C₆)alkyl.

In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ or R₉ is -H.

25 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

30 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

5 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

10 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

15 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

20 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

25 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

30 In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, 10 R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

15 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, 20 R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, and R₈ and R₉ are -H.

25 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, 30 R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

5 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

10 In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

20 In another embodiment, p and m are 0, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 10 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 15 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 20 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 25 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 30 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 10 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 15 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₄ 20 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₄ 25 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ 30 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ 5 is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon 25 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another 30 embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
5 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
10 -C(O)-N(R₄)- group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
15 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
20 -C(O)-N(R₄)- group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the
25 -C(O)-N(R₄)- group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 1, A is -C(O)-N(R₄)-, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the

-C(O)-N(R₄)- group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is halo, x is 1, A is -C(O)-N(R₄)-, R₃ 5 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ 10 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ 15 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ 20 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ 25 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is *tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ 30 is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)- N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is *tert*-butyl. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, and R₈ and R₉ are -H.

10 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In 20 another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, 25 and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

5 In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H,
10 and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

15 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H,
20 and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

25 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H,
30 and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, and R₈ and R₉ are -H.

10 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F.

15 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CH₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -CF₃.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -CF₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -OCH₂CH₃.

25 In another embodiment, p and m are 0, R₁ is -CF₃, x is 0, R₄ is -H, R₈ is -OCH₂CH₃, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

30 In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -halo, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

In another embodiment, p and m are 0, R₁ is -Cl, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

5 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H.

In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl.

10 In another embodiment, p and m are 0, R₁ is -CH₃, x is 0, R₄ is -H, R₈ is -CH₃, and R₉ is -CH₃.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment, R₉ is -Cl. In another embodiment, R₉ is

-Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment, R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 20 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ 25 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ 30 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃

5 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which

10 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃

15 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which

20 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃

25 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to

30 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which 5 the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ 20 group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, 30 R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 5 group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 10 group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 15 group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 20 group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 25 group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 30 group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the

R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 5 group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl 10 group, R₈ is -H, and R₉ is -halo. In another embodiment R₉ is -Cl. In another embodiment, R₉ is -Br. In another embodiment, R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 15 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -halo, and R₉ is -H. In another embodiment R₈ is -Cl. In another embodiment, R₈ is -Br. In another embodiment, R₈ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl

group, R₈ is -H, and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 5 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -CF₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 10 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -H, and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CF₃, x is 0, R₄ is -H, R₃ is -CH₃ 15 and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₈ is -OCH₂CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is 20 attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is 25 attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is 30 attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃

group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration

In another embodiment, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ 5 is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ 10 is -H, R₈ is -*tert*-butyl, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ 15 is -H, R₈ is -H, and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ 20 is -H, R₈ is -CH₃, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another 25 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 30 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, 5 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 10 attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen 15 attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the 20 nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 25 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -halo, x is 30 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -halo, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -Cl, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 1, A is -C(O)-N(R₄)-, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoazoxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoazoxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoazoxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoazoxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzoazoxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridazinyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃ or -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -halo. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 5 benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Cl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -halo, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 10 benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -Cl, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 15 benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -Br. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a thiazanyl group, p is 0, m is 1, R₁ is -CH₃, x is 0, R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the 20 benzooxazolyl group, R₄ is -H, R₈ is -H, and R₉ is -F. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the 25 benzooxazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the 30

carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the
5 carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S configuration.

10 In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the -C(O)-N(R₄)- when x is 1 or the benzooxazolyl group when x is 0 and the carbon to which the R₃ group is attached is in the S
15 configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or
20 thiazanyl group and the carbon to which the R₃ group is attached is in the R configuration.


In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group
25 and the carbon to which the R₃ group is attached is in the R configuration.

In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -(C₁-C₄)alkyl and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or
30 thiazanyl group and the carbon to which the R₃ group is attached is in the S configuration.

In another embodiment, m is 1 and R₃ is -CH₃ and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group. In another embodiment, m is 1 and R₃ is -CH₃, and is attached to the carbon atom adjacent to the nitrogen attached to the pyrazinyl group, pyridazinyl group, or thiazanyl group 5 and the carbon to which the R₃ group is attached is in the S configuration.

4.7 The Compounds of Formula (IVa)

The present invention also encompasses compounds of formula (IVa):



10

(IVa)

and pharmaceutically acceptable salts thereof, where Ar₁, Ar₂, and R₃, are defined above for the Benzoazolylpiperazine Compounds of formula (IVa).

In one embodiment, Ar₁ is a pyridyl group.

20

In another embodiment, Ar₁ is a pyrimidinyl group.

In another embodiment, Ar₂ is a benzothiazolyl group.

In another embodiment, Ar₂ is a benzooxazolyl group.

In another embodiment, Ar₂ is a benzoimidazolyl group.

In another embodiment, n or p is 0.

25

In another embodiment, n or p is 1.

In another embodiment, R₁ is -Cl.

In another embodiment, R₁ is -Br.

In another embodiment, R₁ is -I.

In another embodiment, R₁ is -F.

30

In another embodiment, R₁ is -(C₁-C₆)alkyl.

In another embodiment, R₁ is -CH₃.

- In another embodiment, R₁ is -NO₂.
- In another embodiment, R₁ is -CN.
- In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- 5 In another embodiment, R₁ is -NH₂.
- In another embodiment, R₁ is -C(halo)₃.
- In another embodiment, R₁ is -CH(halo)₂.
- In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, n and p are 1 and R₂ is -halo, -CN, -OH, -O(C₁-C₆)alkyl, -NO₂, or -NH₂.
- 10 In another embodiment, n and p are 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is
- 15 unsubstituted or substituted with one or more R₅ groups.
- In another embodiment, n and p are 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;
- In another embodiment, R₃ is -H.
- 20 In another embodiment, R₃ is -CH₃.
- In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).
- In another embodiment, at least one of R₈ and R₉ is -H.
- 25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H.
- In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H.
- In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo.
- 30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo, and R₉ is -H.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro, and R₉ is -H.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H, and R₉ is -CH₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃, and R₉ is -H.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

20 In another embodiment, Ar₁ Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or, -I; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, 15 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ 30 is a benzothiazolyl group; R₈ is -fluoro, and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo, and R₉ is -H. In another embodiment, the carbon atom 5 to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ 25 is a benzothiazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, 25 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H.

 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group, and R₈ and R₉ are -H.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo.

 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro.

 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro.

 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo.

 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo, and R₉ is -H.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro, and R₉ is -H.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H, and R₉ is -CH₃.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃, and R₉ is -H.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo, and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another

embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F;

- 5 Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,

- Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F;

- Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,

- Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F;

- Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,

- Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is 10 a benzoimidazolyl group; R₈ is -chloro, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro, and R₉ is -H.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is 20 a benzoimidazolyl group; R₈ is -H, and R₉ is -CH₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃, and R₉ is -H.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F;
10 Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is *tert*-butyl; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is *tert*-butyl; and R₉ is -H.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *tert*-butyl.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *tert*-butyl.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl,
20 -Br, or, -I; ; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ 10 is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ 15 is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S 25 configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S 30 configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -chloro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another

embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ 5 is a benzoimidazolyl group; R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, 10 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, 25 -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10

In another embodiment Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; 10 Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, 20 Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -30 Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -chloro, and R₉ is -H.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro, and R₉ is -H.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H, and R₉ is -CH₃.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,
10 Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,
-Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another
15 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,
-Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another
20 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,
-Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another
25 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F,
-Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another
30 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -chloro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

- In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In

another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is R₁ 5 is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -halo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro, and R₉ is -H.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -bromo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -fluoro, and R₉ is -H.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -iodo, and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H, and R₉ is -CH₃.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃, and R₉ is -H.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -H; R₁ is R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group, and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon
5 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom
to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl,
-Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the
carbon atom to which the R₃ group is attached has the R configuration. In another
embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl,
-Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment,
the carbon atom to which the R₃ group is attached has the R configuration. In another
embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl,
20 -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment,
the carbon atom to which the R₃ group is attached has the R configuration. In another
embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl,
-Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment,
25 the carbon atom to which the R₃ group is attached has the R configuration. In another
embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl,
-Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment,
the carbon atom to which the R₃ group is attached has the R configuration. In another
30 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -halo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ 10 is a benzooxazolyl group; R₈ is -bromo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -fluoro, and R₉ is -H. In another embodiment, the carbon atom 15 to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -iodo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, 30 -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom 5 to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ 20 is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another 25 embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 30 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is -F; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₃ is -CH₃; R₁ is R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or, -I; ; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group, and R₈ and R₉ are -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F,
10 Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -halo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro, and R₉ is -H.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -bromo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -fluoro, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F;
30 Ar₂ is a benzooxazolyl group; R₈ is -iodo, and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; ; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H, and R₉ is -CH₃.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃, and R₉ is -H.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃.

In another embodiment Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

In another embodiment, Ar₁ Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H.

35 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H.

40 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -H; R₁ is R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or, -I; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -halo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F;

25 Ar₂ is a benzooxazolyl group; R₈ is -bromo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F;

30 Ar₂ is a benzooxazolyl group; R₈ is -fluoro, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -iodo, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H, and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃, and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.


In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is -F; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₃ is -CH₃; R₁ is R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

4.8 The Compounds of Formula (IVb)

The present invention also encompasses compounds of formula (IVb):



(IVb)

and pharmaceutically acceptable salts thereof, where Ar₁, Ar₂, A, R₃ and x are defined above for the Benzoazolylpiperazine Compounds of formula (IVb).

In one embodiment, Ar₁ is a pyridyl group.

In another embodiment, Ar₁ is a pyrimidinyl group.

- In another embodiment, n or p is 0.
- In another embodiment, n or p is 1.
- In another embodiment, x is 0.
- In another embodiment, x is 1.
- 5 In another embodiment, R₁ is -F.
- In another embodiment, R₁ is -Cl.
- In another embodiment, R₁ is -Br.
- In another embodiment, R₁ is -I.
- In another embodiment, R₁ is -(C₁-C₆)alkyl.
- 10 In another embodiment, R₁ is -CH₃.
- In another embodiment, R₁ is -NO₂.
- In another embodiment, R₁ is -CN.
- In another embodiment, R₁ is -OH.
- In another embodiment, R₁ is -OCH₃.
- 15 In another embodiment, R₁ is -NH₂.
- In another embodiment, R₁ is -C(halo)₃.
- In another embodiment, R₁ is -CH(halo)₂.
- In another embodiment, R₁ is -CH₂(halo).
- In another embodiment, n and p are 1 and R₂ is -halo, -CN, -OH, -O(C₁-
- 20 C₆)alkyl, -NO₂, or -NH₂.
- In another embodiment, n and p are 1 and R₂ is -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is
- 25 unsubstituted or substituted with one or more R₅ groups.
- In another embodiment, n and p are 1 and R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;
- In another embodiment, x is 1 and A is -C(O)N(R₄)-.
- 30 In another embodiment, x is 1, A is -C(O)N(R₄)-, and R₄ is -H.
- In another embodiment, x is 1, A is -C(O)N(R₄)-, and R₄ is -CH₃.

In another embodiment, x is 1 and A is -C(S)N(R₄)-.

In another embodiment, x is 1, A is -C(S)N(R₄)-, and R₄ is -H.

In another embodiment, x is 1, A is -C(S)N(R₄)-, and R₄ is -CH₃.

In another embodiment, Ar₂ is a benzothiazolyl group.

5 In another embodiment, Ar₂ is a benzoimidazolyl group.

In another embodiment, Ar₂ is a benzooxazolyl group.

In another embodiment, R₈ and R₉ are each independently -H, halo, -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo).

In another embodiment, at least one of R₈ or R₉ is -H.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; R₄ is -H; Ar₂ is 15 a benzothiazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 25 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a 20 benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a
10 benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to
15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a
30 benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is *-tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a
10 benzothiazolyl group; R₈ is *-tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *-tert*-butyl. In another embodiment, the
15 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *-tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is *-tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *-tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a
30 benzothiazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, 5 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, R₄ is -H; Ar₂ is a benzothiazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a 10 benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a 15 benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a 20 benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, 30 or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 10 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a 10 benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a 30 benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, R₄ is -H; Ar₂ is a benzoimidazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; 30 Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a 20 benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a 25 benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a
10 benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to
15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a
30 benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to 10 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a
10 benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; R₄ is -H;
30 Ar₂ is a benzoimidazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or 20 -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a 25 benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

35 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a
10 benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom
15 to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a
30 benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

35 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom

to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon 5 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 10 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; 20 R₄ is -H; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; R₄ is -H; Ar₂ is a benzooxazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 30 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; 10 Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon 15 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a 30 benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a 10 benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a 30 benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group, n is 0; R₁ is -CH₃; Ar₂ is a 10 benzooxazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, 15 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, R₄ is -H; Ar₂ is a benzooxazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or 30 -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a 20 benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to 25 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 30 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom

to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl, p is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; R₄ is -H; Ar₂ is a benzothiazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a 10 benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to 15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a 30 benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a 10 benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the 15 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -*tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a 30 benzothiazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; R₄ is -H; Ar₂ is a benzothiazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -Cl; Ar₂ is 10 a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -Cl; Ar₂ is 15 a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, 5 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon
5 atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CH₃; Ar₂ 10 is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CH₃; Ar₂ 15 is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CH₃; Ar₂ 20 is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 30 is a benzothiazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom

to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzothiazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 10 is a benzothiazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 15 is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 20 is a benzothiazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 25 is a benzothiazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 30 is a benzothiazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ 35 is a benzothiazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzothiazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, 5 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; R₄ is -H; Ar₂ is a benzoimidazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a
10 benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a
15 benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a
20 benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -
I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the
carbon atom to which the R₃ group is attached has the R configuration. In another
embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -
I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the
carbon atom to which the R₃ group is attached has the R configuration. In another
embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -
30 I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the

carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 10 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the 5 carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the 10 carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to 5 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a
10 benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to
15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a
30 benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom

to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is *-tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is *-tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *-tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *-tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is *-tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *-tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidinyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; R₄ is -H; Ar₂ is a benzoimidazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -Cl; Ar₂ is 10 a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -Cl; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom 15 to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another 20 embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment,

the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, 5 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 10 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is 10 a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, 15 the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon 20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, 30 Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In

another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -CF₃; Ar₂ is a benzoimidazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyriminidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -*tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -F; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is *tert*-butyl; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -H; and R₉ is *tert*-butyl. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyrimidyl group and p is 0; R₁ is -CH₃; Ar₂ is a benzoimidazolyl group; R₈ is -CH₃; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; R₄ is -H; Ar₂ is a benzoxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; R₄ is -H; Ar₂ is a benzoxazolyl group and R₈ and R₉ are -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -Cl; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

35 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, -Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a
10 benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to
15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon
30

atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F, -Cl, Br, or -I; Ar₂ is a benzoxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -F; Ar₂ is a benzoxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

10 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzoxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

15 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

20 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

30 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CF₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -CF₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

5 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -OCH₂CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CH₃; Ar₂ is a
10 benzooxazolyl group; R₈ is -OCH₂CH₃; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; and R₈ and R₉ are -H. In another embodiment, the carbon atom to
15 which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -halo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon
20 atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -chloro. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

25 In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -bromo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a
30 benzooxazolyl group; R₈ is -H; and R₉ is -fluoro. In another embodiment, the carbon atom to

which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -iodo. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -halo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -chloro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -bromo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -fluoro; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -iodo; and R₉ is -H. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.

In another embodiment, Ar₁ is a pyridyl group and n is 0; R₁ is -CF₃; Ar₂ is a benzooxazolyl group; R₈ is -H; and R₉ is -CH₃. In another embodiment, the carbon atom to which the R₃ group is attached has the R configuration. In another embodiment, the carbon atom to which the R₃ group is attached has the S configuration.